Oligonucleotide Therapy Market Size, Share & Trends Analysis Report By Type (Antisense, Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory, RNAi), By Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Others), By End User (Hospitals, Research Institutes, Others), By Region, And By Segment Forecasts, 2024-2031.

Oligonucleotide Therapy Market Size is valued at USD 5.21 billion in 2023 and is predicted to reach USD 19.92 billion by the year 2031 at a 18.6% CAGR during the forecast period for 2024-2031.

Oligonucleotides are some of the most promising therapeutic mechanisms for a range of hard-to-treat diseases, in particular those caused by genetic mutations. These are Short sequences of artificially created DNA or RNA molecules that attach to matching sequences in messenger RNA or proteins found in specific cells. Subcategories encompass antisense oligonucleotides (ASOs), aptamer RNAs, and RNA interference (RNAi) oligonucleotides. Several pharmaceutical companies were investigating oligonucleotide therapy, a treatment approach that utilizes chemically manufactured small molecule medications resembling nucleotides. These therapies have the potential to exhibit a similar level of specificity as therapeutic antibodies. Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate the cell membrane when administered on their own.

The market for oligonucleotide treatments has grown significantly due to developments in drug delivery technology, nucleic acid chemistry, and a better knowledge of the molecular causes of disease. Antisense oligonucleotides, small interfering RNA (siRNA), microRNA (miRNA) mimics or inhibitors, aptamers, and oligonucleotide-based gene editing tools like CRISPR-Cas9 are important oligonucleotide-based treatment modalities.

Competitive Landscape

Some Major Key Players In The Oligonucleotide Therapy Market:

• BPCI Biotech Holding
• SomaGenics Inc
• Hepion Pharmaceuticals
• Alnylam Pharmaceuticals
• Regulus Therapeutics Inc
• Ionis Pharmaceuticals
• Gilead Sciences, Inc
• Santaris
• InteRNA Technologies B.V.
• Mirage
• Biogen
• Merck KgaA
• Pfizer Inc.
• Other Market Players

Market Segmentation:

The Oligonucleotide Therapy Market is segmented on the basis of type, application and end-user. Based on type, the oligonucleotide therapy market is segmented into antisense, ribozymes, aptamers, miRNA, CpG/Immunostimulatory, and RNAi. Based on application, the oligonucleotide therapy market is segmented into infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases and others. The End User segment consists of Hospitals, Research Institutes, and Others.

Based On Type, The Antisense Oligonucleotide Segment Is Accounted As A Major Contributor To The Oligonucleotide Therapy Market.

The antisense oligonucleotide segment is expected to hold the largest share of the market. This segment's benefit is due to the optimization of enhanced delivery, specificity, affinity, and nuclease resistance with reduced toxicity. Antisense oligonucleotide (ASO) therapies have developed into a prominent class of therapeutics. The antisense oligonucleotide segment of the oligonucleotide therapy market is witnessing unique growth due to its potential to target specific disease-causing genes at the molecular level. Antisense oligonucleotides offer a promising approach for treating genetic disorders, neurological diseases, and various types of cancers by modulating gene expression. Advancements in oligonucleotide chemistry, delivery systems, and personalized medicine are driving the development of novel antisense therapies. With ongoing research as well as clinical trials demonstrating the efficacy and safety of antisense oligonucleotides, this segment is poised for continued expansion and adoption in the field of precision medicine and targeted therapeutics.

The Neurodegenerative Disorders Segment Witnessed A Rapid Growth.

Neurodegenerative disorders are indeed a significant focus within the oligonucleotide therapy market segment. The development of oligonucleotide-based therapies for conditions such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease is gaining momentum. The potential of oligonucleotide therapy to target specific genes and pathways involved in neurodegeneration has sparked interest in addressing these challenging conditions. As research progresses and clinical trials advance, the neurodegenerative disorders segment is expected to play a crucial role in driving innovation & growth within the oligonucleotide therapy market.

In The Region, The North American Oligonucleotide Therapy Market Holds A Significant Revenue Share.

The North American oligonucleotide therapy market is experiencing robust growth driven by major factors such as increasing research and development activities, rising investments in biotechnology and pharmaceutical sectors, and a growing focus on precision medicine. The region's well-established healthcare infrastructure, strong regulatory framework, and presence of market players contribute to market expansion. Ongoing advancements in oligonucleotide chemistry, delivery technologies, and personalized medicine are shaping the landscape of oligonucleotide therapies in North America. In addition, Asia Pacific is projected to grow at a rapid rate in the global Oligonucleotide Therapy Market due to growing healthcare concerns, especially in the aging population.

Recent Developments:

• In May 2023, Chinook Therapeutics and Ionis Pharmaceuticals have partnered to jointly research, develop, and market an antisense oligonucleotide therapeutic aimed at treating a rare and severe chronic kidney disease.

• In March 2023, AusperBio has reported the successful administration of the first dose of AHB-137, an antisense oligonucleotide therapeutic candidate, to a human subject for the treatment of chronic Hepatitis B.

Artificial Intelligence (AI) In Beauty and Cosmetics Market Report Scope

Segmentation of Oligonucleotide Therapy Market-

Oligonucleotide Therapy Market By Type-

• Antisense
• Ribozymes
• Aptamers
• miRNA
• Cpg/Immunostimulatory
• RNAi

Oligonucleotide Therapy Market By Application-

• Infectious Diseases
• Oncology
• Neurodegenerative Disorders
• Cardiovascular Diseases
• Kidney Diseases
• Others

Oligonucleotide Therapy Market By End-User-

• Hospitals
• Research Institutes
• Others

Oligonucleotide Therapy Market By Region-

North America-

• The US
• Canada
• Mexico

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Argentina
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa
• Rest of Middle East and Africa